Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharon Cohen

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Molecular Genetics and Metabolism Reports|October 25, 2022
Plasma porphyrins among end stage renal disease patients and cutaneous symptoms- is there still an association?Shira Goldman, Omri Zidan, Yonatan Edel, et al.
Alzheimer'S & Dementia (New York, N. Y.)|February 15, 2024
The HOPE4MCI study: A randomized double-blind assessment of AGB101 for the treatment of MCI due to ADRichard Mohs, Arnold Bakker, Sharon Rosenzweig-Lipson, et al.
Alzheimer'S & Dementia (New York, N. Y.)|May 8, 2025
Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 yearsMarwan Sabbagh, Cristina Boschini, Sharon Cohen, et al.
Journal of Molecular Medicine (Berlin, Germany)|October 12, 2012
Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2Sharon Cohen, Ilan Bruchim, Dror Graiver, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|February 12, 2020
CHILDREN AND ADOLESCENTS WITH GENDER DYSPHORIA IN ISRAEL: INCREASING REFERRAL AND FERTILITY PRESERVATION RATESAnat Segev-Becker, Galit Israeli, Erella Elkon-Tamir, et al.
Clinical Neuropharmacology|January 22, 2013
Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation studyJaren W Landen, Qinying Zhao, Sharon Cohen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentSharon Cohen, Simon Ducharme, Jared R Brosch, et al.
Nutrients|December 28, 2021
Nutritional Status Impairment Due to Neoadjuvant Chemotherapy Predicts Post-Radical Cystectomy ComplicationsSharon Cohen, Jonathan Gal, Yuval Freifeld, et al.
Paediatric and Perinatal Epidemiology|November 26, 2013
The influence of anxiety and depressive symptoms during pregnancy on birth sizeBirit F P Broekman, Yiong-Huak Chan, Yap-Seng Chong, et al.
Neurology|April 27, 2018
ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer diseaseJeffrey L Cummings, Sharon Cohen, Christopher H van Dyck, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Molecular Genetics and Metabolism Reports|October 25, 2022
Plasma porphyrins among end stage renal disease patients and cutaneous symptoms- is there still an association?Shira Goldman, Omri Zidan, Yonatan Edel, et al.
Alzheimer'S & Dementia (New York, N. Y.)|February 15, 2024
The HOPE4MCI study: A randomized double-blind assessment of AGB101 for the treatment of MCI due to ADRichard Mohs, Arnold Bakker, Sharon Rosenzweig-Lipson, et al.
Alzheimer'S & Dementia (New York, N. Y.)|May 8, 2025
Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 yearsMarwan Sabbagh, Cristina Boschini, Sharon Cohen, et al.
Journal of Molecular Medicine (Berlin, Germany)|October 12, 2012
Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2Sharon Cohen, Ilan Bruchim, Dror Graiver, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|February 12, 2020
CHILDREN AND ADOLESCENTS WITH GENDER DYSPHORIA IN ISRAEL: INCREASING REFERRAL AND FERTILITY PRESERVATION RATESAnat Segev-Becker, Galit Israeli, Erella Elkon-Tamir, et al.
Clinical Neuropharmacology|January 22, 2013
Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation studyJaren W Landen, Qinying Zhao, Sharon Cohen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentSharon Cohen, Simon Ducharme, Jared R Brosch, et al.
Nutrients|December 28, 2021
Nutritional Status Impairment Due to Neoadjuvant Chemotherapy Predicts Post-Radical Cystectomy ComplicationsSharon Cohen, Jonathan Gal, Yuval Freifeld, et al.
Paediatric and Perinatal Epidemiology|November 26, 2013
The influence of anxiety and depressive symptoms during pregnancy on birth sizeBirit F P Broekman, Yiong-Huak Chan, Yap-Seng Chong, et al.
Neurology|April 27, 2018
ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer diseaseJeffrey L Cummings, Sharon Cohen, Christopher H van Dyck, et al.
Pageof 6